A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, randomized, placebo-controlled, single blind, parallel group,
single-center study designed to evaluate immune responses during and after administration of
12 weekly SC doses of 1.0 mg/kg efalizumab in subjects with moderate plaque psoriasis.